Advanced in Subdural Hematoma

Dr. Michael Schulder

Neurosurgery
450 Lakeville Road, Entrance F, 
Lake Success, NY 
On Staff At
Advanced in Subdural Hematoma
450 Lakeville Road, Entrance F, 
Lake Success, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Michael Schulder is a Neurosurgery provider in Lake Success, New York. Dr. Schulder is rated as an Advanced provider by MediFind in the treatment of Subdural Hematoma. His top areas of expertise are Astrocytoma, Glioblastoma, Brain Tumor, Gamma Knife Radiosurgery, and Awake Craniotomy.

His clinical research consists of co-authoring 93 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Columbia University College Of Physicians & Surgeons
Residency
Albert Einstein College of Medicine-Yeshiva University
Specialties
Neurosurgery
Licenses
Neurological Surgery in NJ
Board Certifications
American Board Of Neurological Surgery
Fellowships
Brigham and Womens Hospital
Hospital Affiliations
Long Island Jewish Medical Center
North Shore University Hospital Syosset
Long Island Jewish Forest Hills
Long Island Jewish Valley Stream
Plainview Hospital
Lenox Hill Hospital
North Shore University Hospital
Hofstra/Northwell School Of Medicine/Nursing
Glen Cove Hospital
Northwell Health Institute Of Neurology And Neurosurgery
Cancer Institute
Languages Spoken
English
Hebrew
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

Northwell Health Ambulatory Surgery at the Center for Advanced Medicine
450 Lakeville Road, Entrance F, Lake Success, NY 11042

Additional Areas of Focus

Dr. Schulder has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Trigeminal Neuralgia
Acoustic Neuroma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Multicenter Randomized Phase III Trial on INTraoperative RAdiotherapy in Newly Diagnosed GliOblastoma Multiforme (INTRAGO II)
A Multicenter Randomized Phase III Trial on INTraoperative RAdiotherapy in Newly Diagnosed GliOblastoma Multiforme (INTRAGO II)
Enrollment Status: Active_not_recruiting
Publish Date: October 14, 2025
Intervention Type: Radiation, Procedure, Drug
Study Drug: Temozolomide
Study Phase: Phase 3
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R, in Newly Diagnosed Patients With Glioblastoma
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R, in Newly Diagnosed Patients With Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: September 11, 2025
Intervention Type: Combination product, Procedure, Drug
Study Drugs: IGV-001 Cell Immunotherapy, Temozolomide
Study Phase: Phase 2
A Phase 1/2 Study of Selinexor in Combination With Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Glioblastoma
A Phase 1/2 Study of Selinexor in Combination With Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Glioblastoma
Enrollment Status: Terminated
Publish Date: December 16, 2024
Intervention Type: Drug, Device, Radiation
Study Drugs: Selinexor, Temozolomide (TMZ), Lomustine (CCNU), Bevacizumab, Carmustine
Study Phase: Phase 1/Phase 2
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Enrollment Status: Suspended
Publish Date: April 03, 2024
Intervention Type: Biological
Study Phase: Phase 3
Phase I Study of Subventricular Zone Tumor Stem Cell Stereotactic Radiosurgery With Standard of Care Chemoradiation Therapy in Newly Diagnosed Malignant Gliomas (WHO III and WHO IV Astrocytomas)
Phase I Study of Subventricular Zone Tumor Stem Cell Stereotactic Radiosurgery With Standard of Care Chemoradiation Therapy in Newly Diagnosed Malignant Gliomas (WHO III and WHO IV Astrocytomas)
Enrollment Status: Withdrawn
Publish Date: March 15, 2023
Intervention Type: Radiation
Study Phase: Not Applicable
Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate With Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects
Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate With Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects
Enrollment Status: Terminated
Publish Date: July 22, 2021
Intervention Type: Drug, Other
Study Phase: Phase 3
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Enrollment Status: Terminated
Publish Date: February 07, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2/Phase 3
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: October 23, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 7 Less Clinical Trials

93 Total Publications

Optimizing patient positioning for exoscopic cranial surgery.
Optimizing patient positioning for exoscopic cranial surgery.
Journal: Neurosurgical focus: Video
Published: October 20, 2025
Similar Doctors
Elite in Subdural Hematoma
Dr. Thomas W. Link
Neurosurgery
Elite in Subdural Hematoma
Dr. Thomas W. Link
Neurosurgery

North Shore-Lij Medical PC

300 Community Dr, 
Manhasset, NY 
 (0.1 miles away)
516-562-3058
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Thomas Link is a Neurosurgery provider in Manhasset, New York. Dr. Link is rated as a Distinguished provider by MediFind in the treatment of Subdural Hematoma. His top areas of expertise are Subdural Hematoma, Chronic Subdural Hematoma, Stroke, Transmyocardial Revascularization, and Stent Placement.

Elite in Subdural Hematoma
Dr. Jared Knopman
Neurosurgery
Elite in Subdural Hematoma
Dr. Jared Knopman
Neurosurgery

Weill Medical College Of Cornell

525 E 68th St, 
New York, NY 
 (13.2 miles away)
646-962-3376
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jared Knopman is a Neurosurgery provider in New York, New York. Dr. Knopman is rated as a Distinguished provider by MediFind in the treatment of Subdural Hematoma. His top areas of expertise are Subdural Hematoma, Brain Aneurysm, Chronic Subdural Hematoma, Sacral Nerve Stimulation, and Thrombectomy.

Elite in Subdural Hematoma
Dr. Christopher P. Kellner
Neurosurgery | Neuroradiology
Elite in Subdural Hematoma
Dr. Christopher P. Kellner
Neurosurgery | Neuroradiology

Icahn School Of Medicine At Mount Sinai

1 Gustave Levy Place, Mount Sinai Hospital, 
New York, NY 
 (13.2 miles away)
212-731-6761
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Christopher Kellner is a Neurosurgery specialist and a Neuroradiologist in New York, New York. Dr. Kellner is rated as an Elite provider by MediFind in the treatment of Subdural Hematoma. His top areas of expertise are Stroke, Subarachnoid Hemorrhage, Subdural Hematoma, Thrombectomy, and Gastrostomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Schulder's expertise for a condition
ConditionClose
View All 16 Distinguished Conditions
View All 11 Advanced Conditions
View All 25 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile